Follow-Up Study of Follicular Lymphoma (FL) Treated Using Clarithromycin: Intravenous Erythromycin Combined with Prednisolone Treatment is Effective for Refractory FL Accompanied with an Ocular Lesion
Abstract
A 44-year-old man who presented lymphadenopathy was diagnosed with follicular lymphoma (FL). He was treated with rituximab, cyclophosphamide (CPM), doxorubicin, vincristine, and prednisolone (PSL), which resulted in a stable disease. The patient’s subsequent clinical course included partial remission and stable disease, each of which was treated by chemotherapy. At the third regrowth of the tumor, however, the patient was diagnosed with leukocytopenia and could not undergo further chemotherapy. Regression of his lymphadenopathy occurred following treatment with clarithromycin (CAM), which has anti-lymphoproliferative effects. CAM was continued with good outcome and then CAM was tentatively discontinued. Invasion of the lymphoma cells into the thoracic vertebrae occurred and was successfully treated by radiotherapy. Thereafter, he was successfully treated with CAM combined with PSL and CPM. At 57 years of age, he developed pancytopenia owing to therapy-related myelodysplastic syndrome; consequently, CPM was discontinued. Treatment with CAM combined with PSL was continued successfully. However, 15 months later, he complained of exophthalmos. Magnetic resonance imaging revealed a right orbital lesion. As an alternative to CAM combined with PSL, treatment with intravenous EM combined with PSL was used successfully. This case shows that treatment with intravenous EM combined with PSL may be effective in some cases of refractory FL.
References
Van Nuffel AM, Sukhatme V, Pantziarka P, Meheus L, Sukhatme VP, Bouche G. Repurposing Drugs in oncology (ReDO)―clarithromycin as an anti-cancer agent. Ecancermedicalscience. 2015 24;9:513. doi: 10.3332/ecancer.2015.513.
Lin KT, Wang LH. New dimension of glucocorticoids in cancer treatment. Steroids 2016;111:84-88.
Ohe M, Hashino S. Successful treatment of diffuse large B-cell lymphoma with clarithromycin and prednisolone. Korean J Hematol 2012; 47:293-297.
Ohe M, Hashino S. Successful treatment with clarithromycin for Mixed phenotype acute leukemia, T/myeloid, NOS. Rinsho Ketsueki. 2010;51:297-299.
Ohe M, Hashino S, Shida H, Horita T, Sugiura M. A case of Waldenstrom’s macroglobulinemia treated using clarithromycin and prednisolone. Transl Clin Pharmacol 2017;25:134-137.
Ohe M, Hashino S. A case of follicular lymphoma treated using clarithromycin. Korean J Hematol. 2011; 46:203-206.
Ishimatsu Y, Mukae H, Matsumoto K, Harada T, Hara A, Hara S, et al. Two cases with pulmonary mucosa-associated lymphoid tissue lymphoma successfully treated with clarithromycin. Chest. 2010; 138:730-733.
Ploner C, Schmidt S, Presul E, Presul E, Renner K, Schrocksnadel K, et al. Glucocorticoid-induced apoptosis and glucocorticoid resistance in acute lymphoblastic leukemia. J Steroid Biochem Mol Bio. 2005; 93:153-160.
Ohe M, Hashino S. Successful treatment of recurrent follicular B-cell lymphoma with clarithromycin, prednisolone, and cyclophosphamide. Korean J Intern Med 2013; 28:377-379.
Chu SY, Deaton R, Cavanaugh J. Absolute bioavailability of clarithromycin after oral administration in humans. Antimicrob Agents Chemother. 1992. 36:1147-1150.
Iwasaki H, Sugiura Y, Adachi T, Morimoto S, Watanabe Y. Structure of 6-0-methylerythromycin A (clarithromycin). Acta Cryst 1993;C49:1227-1230.
Pillozzi S, Masselli M, Gasparoli L, D'Amico L, Polletta L, Veltroni M, et al. Macrolide antibiotics have an antileukemic effect by modulating the autophagic flux through the involvement of hERG1 potassium channels. Blood Cancer J 2016; 6:e423.
